爱德华生命科学

US · EW #442 按市值排名上市于 1970

86.60 -1.50 -1.70%

实时 - 追踪5344个代码 - 心跳于204秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了6家。
机构持股总比例下降了0.3个百分点。

机构持股

机构持股比例: 93.18% -0.26pp
机构数量: 1,614 -6
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund78.24%

Hedge Fund4.24%

Public Company3.56%

Government Pension Fund2.17%

Sovereign Wealth Fund1.54%

Private Company1.38%

VC/PE Fund1.17%

Insurance Company0.32%

Individual/Insider0.22%

Other7.15%

主要股东截至 2026-06-30

BlackRock 10.20% · 58.79M 股

Vanguard Capital Management, LLC 7.09% · 40.85M 股

Vanguard Portfolio Management, LLC 4.58% · 26.41M 股

State Street Global Advisors 4.57% · 26.32M 股

J.P. Morgan Asset Management, Inc. 3.38% · 19.49M 股

Wellington Management Group 2.92% · 16.83M 股

Geode Capital Management, LLC 2.68% · 15.44M 股

Ninety One UK Limited 2.29% · 13.22M 股

Union Asset Management Holding AG 2.26% · 13.00M 股

Aristotle Capital Management, LLC 1.50% · 8.67M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 16次买入 · 34次卖出

姓名	职务	持股比例
Scott Ullem	Corporate VP & CFO	0.05%
Larry Wood	Corporate VP and Group President of TAVR & Surgical Structural Heart	0.03%
Jean-Luc Lemercier	Corporate Vice President of Japan, Asia Pacific & Greater China	0.03%
Donald Bobo	Corporate Vice President of Strategy & Corporate Development	0.02%
Bernard Zovighian	Chief Executive Officer	0.02%
Steven Loranger	Independent Director	0.01%
Kieran Gallahue	Independent Director	0.01%
Nicholas Valeriani	Independent Director	0.01%
Leslie Heisz	Independent Director	0.01%
Daveen Chopra	Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies	0.00%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-13	Wayne Markowitz	GM & Senior VP of Surgical	Sale to Issuer	-923	$84.37–86.77
2026-09-12	Andrew Dahl	Officer	Sale to Issuer	-253	$84.37
2026-09-10	Daveen Chopra	Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies	Sale to Issuer	-398	$86.77
2026-09-10	Daniel Lippis	CVP of JAPAC	Derivative Exercise and Sale	-619	$72.68–87.51
2026-08-30	Andrew Dahl	Officer	Open Market Disposition	-544	$91.06
2026-08-27	Annette Bruls	Corporate Vice President of EMEA, Canada, & Latin America	Open Market Disposition	-2,644	$89.98
2026-08-25	Daveen Chopra	Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies	Derivative Exercise and Sale	-31,800	$72.68–91.76
2026-08-25	Wayne Markowitz	GM & Senior VP of Surgical	Open Market Disposition	-1,240	$91.47
2026-08-10	Daniel Lippis	CVP of JAPAC	Derivative Exercise and Sale	-619	$72.68–92.03
2026-07-29	Scott Ullem	Corporate VP & CFO	Intent to Sell (Form 144)	-50,000	$92.50
2026-07-29	Wayne Markowitz	GM & Senior VP of Surgical	Open Market Disposition	-146	$86.03
2026-07-27	Wayne Markowitz	GM & Senior VP of Surgical	Derivative Exercise and Sale	-9,628	$74.02–85.06
2026-07-26	Bernard Zovighian	Chief Executive Officer	Other Acquisition	+319	--
2026-07-26	Bernard Zovighian	Chief Executive Officer	Other Disposition	-319	--
2026-07-26	Bernard Zovighian	Chief Executive Officer	Open Market Disposition	-2,920	$83.93
2026-07-10	Annette Bruls	Corporate Vice President of EMEA, Canada, & Latin America	Sale to Issuer	-109	$92.21
2026-07-09	Daniel Lippis	CVP of JAPAC	Derivative Exercise and Sale	-619	$72.68–91.70
2026-07-08	Theodora Mistras	Corporate VP & CFO	Other Acquisition	+99,920	--
2026-07-08	Theodora Mistras	Corporate VP & CFO	Other Derivative Acquisition	+12,325	--
2026-07-08	Theodora Mistras	Corporate VP & CFO	Other Derivative Acquisition	+61,800	$91.33

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。